Wedge Capital Management’s ImmuCell ICCC Stock Holding History

Wedge Capital Management’s Portfolio ICCC Stock Details ICCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-20,384	Closed	-$197K	–	459
2021 Q1	$197K	Buy	+20,384	New	+$191K	﹤0.01%	504

Other funds holding ICCC

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OMC

Overbrook Management Corp New York $663M AUM 35.04% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PCM

Perritt Capital Management Chicago, Illinois $59.8M AUM 26.94% 1-Year Est. Return

SFS

Strategic Financial Services Utica, New York $2.1B AUM 19.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SRC

Shufro Rose & Co New York $1.47B AUM 19.38% 1-Year Est. Return

Wedge Capital Management's ICCC Position: Q2 2021 in Review

Wedge Capital Management sold out of ImmuCell (ICCC) in Q2 2021, closing a stake of 20,384 shares — an estimated $197K sold.

Wedge Capital Management first reported a position in ICCC in Q1 2021 and held it in 1 quarter. The position peaked at $197K in Q1 2021. 28 funds tracked by Wall St. Rank hold ICCC as of Q2 2021.

Wedge Capital Management reported no remaining ImmuCell position as of Q2 2021 after selling out during the quarter.
Wedge Capital Management sold 20,384 ImmuCell shares in Q2 2021, an estimated $197K.
Wedge Capital Management first reported a position in ImmuCell in Q1 2021 and held it in 1 quarter.
Wedge Capital Management's ImmuCell position peaked at $197K in Q1 2021.
28 funds tracked by Wall St. Rank held ImmuCell as of Q2 2021.

Based on Wedge Capital Management's 13F filing for Q2 2021, filed 14 Jul 2021.